We are a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.
Quote | Fortress Biotech Inc. (NASDAQ:FBIO)
Last: | $0.3101 |
---|---|
Change Percent: | 1.67% |
Open: | $0.3005 |
Close: | $0.305 |
High: | $0.3175 |
Low: | $0.3 |
Volume: | 31,872 |
Last Trade Date Time: | 09/28/2023 03:00:00 am |
News | Fortress Biotech Inc. (NASDAQ:FBIO)
2023-09-27 14:04:27 ET More on Fortress Biotech Stocks To Watch: Investors Prep For Inflation Data And Q2 Earnings Rush Journey Medical announces exclusive license agreement with Maruho Journey Medical stock rallies 20% on Phase 3 studies update Seeking Alpha...
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel prese...
Message Board Posts | Fortress Biotech Inc. (NASDAQ:FBIO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $FBIO News Article - Checkpoint Therapeutics Announces $6.1 Million Registered Direct O | whytestocks | investorshangout | 03/31/2023 5:40:56 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation Reports Full-Year 2022 Financial Resul | whytestocks | investorshangout | 03/29/2023 8:26:10 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation to Participate in the 35th Annual ROTH | whytestocks | investorshangout | 03/07/2023 6:35:47 PM |
Has $FBIO gotten a NASDAQ warning letter yet? | Spicknspan | investorshub | 02/28/2023 12:20:02 AM |
whytestocks: $FBIO News Article - Helocyte, Inc. Announces Positive Data from Stem Cell Transplant D | whytestocks | investorshangout | 02/16/2023 7:40:48 PM |
Fortress Biotech Inc. Company Name:
FBIO Stock Symbol:
NASDAQ Market:
Fortress Biotech Inc. Website:
The Dow Jones closed lower by around 69 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around...
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy an...
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel prese...